Smaller Doses, Smaller Footprint: How Low-Dose HIV Prevention Could Cut Costs and Carbon

Uganda’s Lenacapavir Launch: Five Early Lessons for Turning Innovation into Access

What CATALYST Still Has to Teach Us

From Launch to Life: Why Retention Will Define the Future of HIV PrEP

From Disruption to Delivery: What It Really Takes to Turn Breakthroughs Into Access

When Systems Fail, Communities Lead: What One Year of Aid Cuts Has Taught Us About HIV Prevention

Reflecting Back on 2025: A Year of Hard Transitions, Quiet Courage, and Unshakable Hope

Duty-Free, but at a Cost

A Billion-Dollar Question: Will Investments in Implementation Science Accelerate Lenacapavir’s Impact?

Improving the Bridge: Accelerating Product Innovation and Sustainability

Staying the Course: What Leadership Looks Like When the Funding Stops

Coordination Is Everyone’s Job

AI after Kigali: Navigating Hope and Hard Questions

Don’t Just Push: Addressing How We Deliver New Health Products